CDK4 and breast carcinoma: This study further utilized a triple combination approach including neratinib, CDK4/6 inhibitor, and endocrine therapy, to assess the impact of HER2 on the efficacy of CDK4/6 inhibitor combined with endocrine therapy in HR+/HER2-low breast cancer.